Researchers unlock new insights into hard-to-treat neuroendocrine tumors

Researchers at Boston Medical Center and Dana-Farber Cancer Institute conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single cell resolution, unlocking new insights into this rare and often hard-to-treat cancer.

FDA grants priority review for Neurocrine’s crinecerfont NDAs

The asset is intended to treat congenital adrenal hyperplasia in paediatric and adult patients. Credit: YURIMA / Shutterstock. The US Food and Drug Administration (FDA)

July 2, 2024

A Big Bet Goes Bad

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

May 24, 2024

Sana narrows focus again to zero in on diabetes and autoimmune disease

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.